NEW YORK, May 20, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that Phase 1 testing data will be presented at the 2021 ASCO Annual
Meeting June 4, 2021. The
presentation of the data will be by Dr. Scott Tagawa, a Professor of Medicine &
Urology at Weill Cornell Medicine and an AIkido Pharma Scientific
Advisory Board member.
ASCO Presentation Details:
Title: "Phase I study of 225Ac-J591 for men with
metastatic castration-resistant prostate cancer (mCRPC)"
Tract: Genitourinary Cancer—Prostate, Testicular, and
Presenter: Dr. Scott Tagawa
MD, MS, FACP
Abstract Number: 5015
Date and Time: Available Starting June 4, 2021, 9:00 am
The Abstract from this study has been released on the ASCO
Annual Meeting website (https://conferences.asco.org), a portion of
which states: "PSMA-targeted alpha-emitter 225Ac utilizing intact
antibody J591 is tolerable with early evidence of clinical
activity. Based upon these results, a follow up study [NCT04506567]
testing multiple and fractionated dosing of 225Ac-J591 is underway.
Clinical trial information: NCT03276572
The full ASCO meeting program is available at: www.asco.org
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers, and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of
Austin and University of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Brett Maas, Managing Partner
Phone: (646) 536-7331
AIkido Pharma Inc.:
View original content to download
SOURCE AIkido Pharma Inc.